🇺🇸 FDA
Pipeline program

Lucinactant

KL4-AHRF-01

Phase 2 small_molecule completed

Quick answer

Lucinactant for Acute Hypoxemic Respiratory Failure is a Phase 2 program (small_molecule) at WINDTREE THERAPEUTICS INC /DE/ with 1 ClinicalTrials.gov record(s).

Program details

Company
WINDTREE THERAPEUTICS INC /DE/
Indication
Acute Hypoxemic Respiratory Failure
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials